Kyverna Therapeutics is trading at $6.15, down 5.67%, with biotech-sector weakness potentially contributing to the decline. - Biotech was 2.01% lower pre-market amid negative news at several companies. - Kyverna’s investor-relations page lists September 24 clinical data as its latest release; no fresh company-specific announcement was identified. - Broader-market futures were higher, so the decline is out of step with the described risk-on tone; evidence points to sector pressure, not a confirmed company-specific catalyst.